235 related articles for article (PubMed ID: 25960213)
21. [Docetaxel].
Takigawa N
Nihon Rinsho; 2002 May; 60 Suppl 5():349-52. PubMed ID: 12101686
[No Abstract] [Full Text] [Related]
22. Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup.
Zarogoulidis P; Petridis D; Ritzoulis C; Darwiche K; Spyratos D; Huang H; Goldberg EP; Yarmus L; Li Q; Freitag L; Zarogoulidis K
Int J Pharm; 2013 Sep; 453(2):480-7. PubMed ID: 23769993
[TBL] [Abstract][Full Text] [Related]
23. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Cappuzzo F; Rocha Lima CM; Sherman CA; Green MR
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):7-14. PubMed ID: 10960939
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
Abratt RP; Lee JS; Han JY; Tsai CM; Boyer M; Mok T; Kim SW; Lee JS; Brnabic AJ; Reece WH; Lehnert M
J Thorac Oncol; 2006 Feb; 1(2):135-40. PubMed ID: 17409842
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
Shepherd FA
Semin Oncol; 1999 Feb; 26(1 Suppl 4):3-11. PubMed ID: 10201515
[TBL] [Abstract][Full Text] [Related]
26. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of drug therapy of lung cancer in Hungary].
Moldvay J; Rokszin G; Abonyi-Tóth Z; Katona L; Kovács G
Magy Onkol; 2013 Mar; 57(1):33-8. PubMed ID: 23573520
[TBL] [Abstract][Full Text] [Related]
28. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
[TBL] [Abstract][Full Text] [Related]
29. [Chemotherapy for elderly patients with lung cancer].
Okamoto H; Watanabe K
Nihon Rinsho; 2002 May; 60 Suppl 5():591-5. PubMed ID: 12101743
[No Abstract] [Full Text] [Related]
30. Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer.
Zhao Y; Wang Z; Shi X; Liu T; Yu W; Ren X; Zhao H
Technol Cancer Res Treat; 2023; 22():15330338231202307. PubMed ID: 37728201
[No Abstract] [Full Text] [Related]
31. Chemoresistance in non-small cell lung cancer.
Sève P; Dumontet C
Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):73-88. PubMed ID: 15720263
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Ornstein DL; Nervi AM; Rigas JR
Ann Oncol; 1999; 10 Suppl 5():S35-40. PubMed ID: 10582137
[TBL] [Abstract][Full Text] [Related]
33. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
Chen YM; Perng RP; Lee YC; Shih JF; Lee CS; Tsai CM; Whang-Peng J
Ann Oncol; 2002 Jan; 13(1):108-15. PubMed ID: 11863090
[TBL] [Abstract][Full Text] [Related]
35. The development of gemcitabine and carboplatin in the treatment of non-small-cell lung cancer.
Cullen M
Lung Cancer; 2005 Oct; 50 Suppl 1():S5-7. PubMed ID: 16291432
[TBL] [Abstract][Full Text] [Related]
36. [Second-line and beyond: Docetaxel in the treatment of non-small-cell lung cancer].
Rinaldi M
Tumori; 2001; 87(6):A6-9. PubMed ID: 11995708
[No Abstract] [Full Text] [Related]
37. Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis.
Li C; Sun Y; Pan Y; Wang Q; Yang S; Chen H
Lung; 2010 Oct; 188(5):359-64. PubMed ID: 20703493
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
39. Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Pectasides D; Aspropotamitis A; Halikia A; Visvikis A; Antoniou F; Kalantaridou A; Karvounis N; Batzios S; Athanassiou A
J Clin Oncol; 1999 Dec; 17(12):3816-21. PubMed ID: 10577854
[TBL] [Abstract][Full Text] [Related]
40. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Georgoulias V; Papadakis E; Alexopoulos A; Tsiafaki X; Rapti A; Veslemes M; Palamidas P; Vlachonikolis I;
Lancet; 2001 May; 357(9267):1478-84. PubMed ID: 11377599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
